30 Day Trial
ORTHOKNOW logo

ORTHOKNOW content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Quarterly Review

3Q13 Revenue: TiGenix

ChondroCelect €0.8MM (~US $1.1MM), -27%

  • Expects full-year sales growth +20%, fueled by revenue in Belgium and the Netherlands
  • Raised €6.5MM (~US $8.8MM) via private placement
  • In 4Q, received renewal of GMP license for cell therapy manufacturing facility in Netherlands